S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China

Citius Pharmaceuticals - CTXR Price Target & Analyst Ratings

$1.32
+0.01 (+0.76%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.35
50-Day Range
$0.78
$1.40
52-Week Range
$0.77
$2.01
Volume
770,397 shs
Average Volume
1.23 million shs
Market Capitalization
$193.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Citius Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$4.00
203.03% Upside
High Prediction$4.00
Average Prediction$4.00
Low Prediction$4.00
TypeCurrent
1/29/22 to 1/29/23
1 Month Ago
12/30/21 to 12/30/22
3 Months Ago
10/31/21 to 10/31/22
1 Year Ago
1/29/21 to 1/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.00$5.00$5.00$5.33
Predicted Upside203.03% Upside224.15% Upside224.15% Upside195.48% Upside
Get Citius Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.


CTXR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CTXR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Citius Pharmaceuticals Stock vs. The Competition

TypeCitius PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside203.03% Upside1,053.64% Upside9.89% Upside
News Sentiment RatingVery Positive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/11/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Okunewitch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00+164.90%
1/18/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$4.00 ➝ $6.00+280.95%
2/25/2021Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$6.00+170.27%
(Data available from 1/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CTXR Price Target - Frequently Asked Questions

What is Citius Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. The average twelve-month price prediction for Citius Pharmaceuticals is $4.00 with a high price target of $4.00 and a low price target of $4.00. Learn more on CTXR's analyst rating history.

Do Wall Street analysts like Citius Pharmaceuticals more than its competitors?

Analysts like Citius Pharmaceuticals more than other Medical companies. The consensus rating score for Citius Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how CTXR compares to other companies.

Does Citius Pharmaceuticals's stock price have much upside?

According to analysts, Citius Pharmaceuticals's stock has a predicted upside of 164.90% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:CTXR) was last updated on 1/29/2023 by MarketBeat.com Staff